Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Iron chelating agent, deferoxamine, induced apoptosis in Saos-2 osteosarcoma cancer cells

Saos-2 골육종 세포에서 iron chelating agent, deferoxamine에 의한 apoptosis 유도

  • Park, Eun Hye (Research Institute of Clinical Medicine, School of Medicine Chonbuk National University) ;
  • Lee, Hyo Jung (Department of Pediatrics, School of Medicine Chonbuk National University) ;
  • Lee, Soo Yeon (Department of Pediatrics, School of Medicine Chonbuk National University) ;
  • Kim, Sun Young (Research Institute of Clinical Medicine, School of Medicine Chonbuk National University) ;
  • Yi, Ho Keun (Department of Biochemistry, School of Dentistry, Chonbuk National University) ;
  • Lee, Dae Yeol (Department of Pediatrics, School of Medicine Chonbuk National University) ;
  • Hwang, Pyoung Han (Department of Pediatrics, School of Medicine Chonbuk National University)
  • 박은혜 (전북대학교 의과대학 임상의학연구소) ;
  • 이효정 (전북대학교 의과대학 소아과학교실) ;
  • 이수연 (전북대학교 의과대학 소아과학교실) ;
  • 김선영 (전북대학교 의과대학 임상의학연구소) ;
  • 이호근 (전북대학교 치과대학 생화학교실) ;
  • 이대열 (전북대학교 의과대학 소아과학교실) ;
  • 황평한 (전북대학교 의과대학 소아과학교실)
  • Received : 2009.12.25
  • Accepted : 2009.01.19
  • Published : 2009.02.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose:Iron is a critical nutritional element that is essential for a variety of important biological processes, including cell growth and differentiation, electron transfer reactions, and oxygen transport, activation, and detoxification. Iron is also required for neoplastic cell growth due to its catalytic effects on the formation of hydroxyl radicals, suppression of host defense cell activities, and promotion of cancer cell multiplication. Chronic transfusion-dependent patients receiving chemotherapy may have iron overload, which requires iron-chelating therapy. We performed this study to demonstrate whether the iron chelating agent deferoxamine induces apoptosis in Saos-2 osteosarcoma cells, and to investigate the underlying apoptotic mechanism. Methods:To analyze the apoptotic effects of an iron chelator, cultured Saos-2 cells were treated with deferoxamine. We analyzed cell survival by trypan blue and crystal violet analysis, apoptosis by nuclear condensation, DNA fragmentation, and cell cycle analysis, and the expression of apoptotic related proteins by Western immunoblot analysis. Results:Deferoxamine inhibited the growth of Saos-2 cell in a time- and dose-dependent manner. The major mechanism for growth inhibition with the deferoxamine treatment was by the induction of apoptosis, which was supported by nuclear staining, DNA fragmentation analysis, and flow cytometric analysis. Furthermore, bcl-2 expression decreased, while bax, caspase-3, caspase-9, and PARP expression increased in Saos-2 cells treated with deferoxamine. Conclusion:These results demonstrated that the iron chelating agent deferoxamine induced growth inhibition and mitochondrial-dependent apoptosis in osteosarcoma Saos-2 cells, suggesting that iron chelating agents used in controlling neoplastic cell fate can be potentially developed as an adjuvant agent enhancing the anti-tumor effect for the treatment of osteosarcoma.

목 적:철은 세포 성장과 분화, 전자 전달 반응, 산소 전달, 해독작용 등 여러 가지 중요한 생체 반응에 반드시 필요한 요소로서 종양세포의 성장과 증식에도 절대적으로 필요하다. 최근에 철킬레이트제인 deferoxamine이 악성 구강 각질세포의 성장을 억제하고 세포자멸사를 유도하며, 난소암세포의 증식을 억제하고 세포자멸사를 유도하여 난소암의 성장을 억제하였다고 보고되었다. 그러므로 반복적인 수혈에 의하여 헤모시데린침착증이 발생한 소아 종양 환아에서 deferoxamine이 철을 제거 할 뿐만 아니라 암세포의 세포자멸사를 유도하는지에 대하여 알아보고 세포자멸사를 유도한다면 그 경로에 대하여 알아보고자 하였다. 방 법:골육종세포인 Saos-2에서 deferoxamine에 대한 효과를 알아보기 위하여 크리스탈 바이올렛과 트리판 블루 염색으로 세포의 성장 및 증식을 측정하였고, DNA 분획, 핵 응축, 세포주기분석으로 세포자멸사를 분석하였고, 세포자멸사와 관련된 분자들의 발현을 Western hybridization으로 분석하였다. 결 과:Deferoxamine은 Saos-2 세포에 대하여 시간과 농도에 의존적으로 세포 증식 억제 효과를 나타내었다. 이러한 세포 증식 억제 효과는 DNA 단편화, 핵 응축, 세포주기 분석에서의 $A_{0}$ 기의 증가, PARP의 활성도의 증가 등 세포자멸사가 유도되었음을 알 수 있었다. 또한 Saos-2 세포에서 deferoxamine 처리 후 Akt/PKB의 활성화가 억제되어 caspase 9의 활성화, 그 하류의 caspase 3의 활성화로 이어지는 미토콘드리아 매개되는 경로로 세포자멸사가 유도되었다. 결 론:결론적으로 철킬레이트제인 deferoxamine이 세포증식을 억제시키고 세포자멸사를 유도시킴으로써 골육종 세포의 증식을 억제하는 것을 보여주었다. 따라서 반복적 대량 수혈에 의한 철 과부하에 따른 장기손상이 우려되는 각종 소아 종양환자들에서 deferoxamine은 체내 축적된 철을 제거할 뿐만 아니라 종양 환자의 치료에 있어서 항암제 치료의 효과를 증가시킬 수 있는 새로운 치료법으로 개발될 수 있을 것이다.

Keywords

References

  1. Papanikolaou G, Pantopoulos K. Iron metabolism and toxicity. Toxicol Appl Pharmacol 2005;202:199-211 https://doi.org/10.1016/j.taap.2004.06.021
  2. Engle JP, Polins KS, Stile IL. Acute iron intoxication: treatment controversies. Drug intell Clin Pharm 1987;21:153-9
  3. Henreting FM, Temple AR. Acute iron poisoning in children. Emerg Med Clin North Am 1984;2:121-32
  4. Schauben JL, Augenstein WL, Cox J, Sato R. Iron poisoning: Report of three cases and a review of therapeutic intervention. J Emerg Med 1990;8:309-19 https://doi.org/10.1016/0736-4679(90)90012-K
  5. Proudfoot AT, Simpson D, Dyson EH. Management of acute iron poisoning. Med Toxicol 1986;1:83-100
  6. Cooper B, Bunn HF, Propper RD, Nathan DG, Rosenthal DS, Moloney WC. Treatment of iron overload in adults with continuous parenteral Deferoxamine. Am J Med 1977; 63:958-66 https://doi.org/10.1016/0002-9343(77)90551-4
  7. Cohen AR, Mizanin JM, Schwartz E. Rapid removal of excessive iron with daily, high dose intravenous chelation therapy. J Pediatr 1989;115:151-5 https://doi.org/10.1016/S0022-3476(89)80353-1
  8. Van der wal NA, Van Oirsschot JF, Van Dijk A, Verhoef J, van Asbeck BS. Mechanism of protection of alveolar type2 cells against paraquat-induced cytotoxicity by deferoxamine. Biochem Pharmacol 1990;39:1665-71 https://doi.org/10.1016/0006-2952(90)90109-X
  9. Kohen R, Chevion M. Paraquant toxicity is enhanced by iron and induced by deferoxamine in laboratory mice. Biochem Pharmac 1984;34:1841-3
  10. Lee JH, Cho B, Jeong DC, Kim HK. Effect of desferrioxamine therapy in patients with transfusional hemosidersis due to severe aplastic anemia. Korean J Pediatr Hematol Oncol 1997;4:62-9
  11. Watanabe BI, Limm W, Suehiro A, Suehiro G, Premaratne S, McNamara JJ. Failure of deferoxamine to reduce myocardial infarct size in a primate model of ischemia-reperfusion injury. J Surg Res 1993;55:537-42 https://doi.org/10.1006/jsre.1993.1180
  12. Kang SA, Jang YJ, Park H. In vivo dual effects of vitamin C on paraquat-induced lung damage: dependence on released metals from the damaged tissue. Free Radic Res 1998;28:93-107 https://doi.org/10.3109/10715769809097880
  13. Lee SK, Lee JJ, Lee HJ, Lee J, Jeon BH, Jun CD, et al. Iron chelator-induced growth arrest and cytochrome c-dependent apoptosis in immortalized and malignant oral keratinocytes. J Oral Pathol Med 2006;35:218-26 https://doi.org/10.1111/j.1600-0714.2006.00415.x
  14. Brard L, Granai CO, Swamy N. Iron chelators deferoxamine and diethylenetriamine pentaacetic acid induce apoptosis in ovarian carcinoma. Gynecol Oncol 2006;100:116-27 https://doi.org/10.1016/j.ygyno.2005.07.129
  15. McLaren GD, Muir WA, Kellermeyer RW. Iron overload diso der: natural history, pathogenesis, diagnosis, and therapy. Crit Rev Clin Lab Sci 1983;19:205-61 https://doi.org/10.3109/10408368309165764
  16. Olson LJ, Edwards WD, McCall JT, Ilstrup DM, Gersh BJ. Cardiac iron deposition in idiopathic hemochromatosis: histologic and analytic assessment of 14 hearts from autopsy. J Am Col Cardiol 1987;10:1239-43 https://doi.org/10.1016/S0735-1097(87)80124-9
  17. Freeman AP, Giles RW, Berdoukas VA, Walsh WF, Choy D, Murray PC. Early left ventricular dysfuntion and chelation theraphy in thalassemia major. Ann Intern Med 1983; 99:450-4
  18. Keberle H. The biochemistry of desferrioxamine and its relation to iron metabolism. Ann N Y Acad Sci 1964;119:758- 68 https://doi.org/10.1111/j.1749-6632.1965.tb54077.x
  19. Liu X, Kim CN, Yang J, Jemmerson R, Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 1996;86:147-57 https://doi.org/10.1016/S0092-8674(00)80085-9
  20. Wallach D, Boldin M, Varfolomeev E, Beyaert R, Vandenabeele P, Fiers W. Cell death induction by receptors of the TNF family: towards a molecular understanding. FEBS Lett 1997;410:96-106 https://doi.org/10.1016/S0014-5793(97)00553-X
  21. Tsujimoto Y, Cossman J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985;228:1440-3 https://doi.org/10.1126/science.3874430
  22. Jurgensmeier JM, Xie Z, Deveraux Q, Ellerby L, Bredesen D, Reed JC. Bax directly induces release of cytochrome C from isolated mitochondria. Proc Natl Acad Sci USA 1998; 95:4997-5002 https://doi.org/10.1073/pnas.95.9.4997
  23. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, et al. Cytochrome C and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997;91:479-89 https://doi.org/10.1016/S0092-8674(00)80434-1
  24. Hu Y, Benedict MA, Wu D, Inohara N, Nunez G. Bcl-XL interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation. Proc Natl Acad Sci USA 1998;95:4386-91 https://doi.org/10.1073/pnas.95.8.4386
  25. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998;281:1312-6 https://doi.org/10.1126/science.281.5381.1312
  26. Kandel ES, Hay N. The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp Cell Res 1999;253:210-29 https://doi.org/10.1006/excr.1999.4690